
Data from a single-center study show that in patients with multidrug-resistant (MDR) Pseudomonas aeruginosa infections, resistance occurred more commonly among those treated with ceftazidime-avibactam (CZA) than those treated with ceftolozane-tazobactam (C/T), researchers reported last week in Clinical Infectious Diseases.
The study, conducted at the University of Pittsburgh Medical Center, included 113 adult patients (median age, 64 years; 63% male) with MDR P aeruginosa pneumonia or bacteremia. The aim of the study was to follow patients for 90 days after treatment with CZA or C/T.
While both are considered first-line agents for MDR P aeruginosa infections, rates of resistance following treatment have not been established. The primary endpoint was development of resistance within 90 days of treatment initiation, defined as a four-fold increase in the minimum inhibitory concentration (MIC) from baseline.
Ninety-three patients in the study received C/T, and 20 received CZA. Patient demographics, severity of illness, and treatment characteristics were similar for patients treated with either agent. Rates of 30-day survival, microbiologic failure, and recurrent infections did not vary between the two groups.
Analysis of 107 patient isolates found a four-fold MIC increase from baseline in 40% (8 of 20) of patients treated with CZA and 10% (9/87) treated with C/T. A planned subgroup analysis of 63 patients treated from 2019 through 2021 showed rates of treatment-emergent resistance of 44% (8/18) in patients treated with CZA and 13% (6/45) in those who received C/T.
Larger studies needed
Whole-genome sequencing showed that CZA resistance was associated with new mutations in ampC and efflux regulatory pathways. The researchers did not identify any clinical factors associated with resistance.
The study authors say their findings, which are limited by the small number of patients treated with CZA and the single-center design of the study, "require validation in real-world multicenter studies aimed to assess the comparative effectiveness of these agents."